Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development declines year over year

Q3 FY2026 research & development of $49.34M fell 34.4% year over year, behind the -19.7% change in trailing-twelve-month research & development. Sequentially, it fell 16.2% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Research & development amounted to 114.0% of revenue in FY2025, down 58.1 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -34.4% toward the trailing-twelve-month pace of -19.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$49.34M-16.2% QoQ
Last fiscal yearDec 2025
$300.27M+6.4% YoY
LTMSep 2026
$241.88M-19.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.4%——
1 year+6.4%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
300.27M USD
Year-over-year change
+6.4%
4-year CAGR
+3.8%

Research & Development vs competitors

How IOVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.7% is the 7th highest of 10, against a peer median of -0.6%.
  • Research & development amounts to 63.8% of revenue for IOVA, versus a peer median of 82.6%.
IOVA Competitors
Research & Development for IOVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
GMABGenmab A/SLTM Jun 2026$1.78B USD—-34.5%43.1%
LEGNLegend Biotech CorporationLTM Sep 2026$378.58M USD-9.4%+7.3%27.9%
IMCRImmunocore Holdings plcLTM Mar 2026$259.11M USD+17.2%+34.4%67.2%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M USD+33.2%-5.7%138.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$241.88M USD-19.7%+0.6%63.8%
IMNMImmunome, Inc.LTM Sep 2026$236.54M USD+35.6%+95.7%—
REPLReplimune Group, Inc.LTM Dec 2025$223.39M USD+26.2%+32.9%—
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M USD-23.9%-30.4%1590.8%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M USD-38.5%-7.9%—
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
Peer median (excluding IOVA) —-0.6%+0.8%82.6%

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.